Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov-Dec;19(6):490-501.
doi: 10.1097/PPO.0000000000000006.

Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer

Sabrin Husein Albeituni  1 , Chuanlin Ding, Jun Yan
Affiliations
Review

Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer

Sabrin Husein Albeituni et al. Cancer J. 2013 Nov-Dec.

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with suppressive properties that preferentially expand in cancer. Myeloid-derived suppressor cells mainly suppress T-cell proliferation and cytotoxicity, inhibit natural killer cell activation, and induce the differentiation and expansion of regulatory T cells. The wide spectrum of MDSC suppressive activity in cancer and its role in tumor progression have rendered these cells a promising target for effective cancer immunotherapy. In this review we briefly discuss the origin of MDSCs and their main mechanisms of suppression and focus more on the approaches developed up to date targeting of MDSCs in tumor-bearing animals and cancer patients.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors declare no financial conflict of interest with this work.

Figures

Figure 1
Figure 1
The main therapeutic compounds targeting MDSC suppression, expansion, recruitment and differentiation in cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci. 2013;1284:1–5. - PMC - PubMed
    1. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today. 1997;18(4):175–182. - PubMed
    1. Maier T, Holda JH, Claman HN. Murine natural suppressor cells in the newborn, in bone marrow, and after cyclophosphamide. Genetic variations and dependence on IFN-gamma. J Immunol. 1989;143(2):491–498. - PubMed
    1. Schmidt-Wolf IG, et al. T-cell subsets and suppressor cells in human bone marrow. Blood. 1992;80(12):3242–3250. - PubMed
    1. Angulo I, et al. Involvement of nitric oxide in bone marrow-derived natural suppressor activity. Its dependence on IFN-gamma. J Immunol. 1995;155(1):15–26. - PubMed

Publication types

Substances